Fluciclovine F-18
Brand Names: Axumin
Methodology & AI Transparency ⓘ
Fluciclovine F-18 Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
- 2 Real-world patient consensus: Zero-PHI community consensus: 93% favorable across 6 logged regimens (Axumin).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $77.75 cash mean against $190.49 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Fluciclovine F-18 tolerability events: application-site irritation (5%), nausea (8.5%), headache (7.1%).
Ask our AI Specialists anything about Fluciclovine F-18
Fluciclovine F-18 Mechanism, CYP450 Pathways & DailyMed Monograph
Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Axumin is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment ( 1 ).
12.1 Mechanism of action Fluciclovine F 18 is a synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells. Fluciclovine F 18 is taken up to a greater extent in prostate cancer cells compared with surrounding normal tissues.
Following administration (221 mCi/mL Injection, Solution), Fluciclovine F-18 achieves Complete (~100%) parenteral systemic delivery for Fluciclovine F-18 (221 mCi/mL Injection, Solution) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after fluciclovine f-18 administration onset, governed by a Mean elimination half-life of 7 to 20 hours across adult Fluciclovine F-18 dosing terminal half-life through dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of fluciclovine f-18.
Before initiating Fluciclovine F-18 at 221 mCi/mL Injection, Solution, clinical safety checklists rule out confirmed ige-mediated allergy or cutaneous reaction to fluciclovine f-18 (fluciclovine f-18) components; uncompensated hepatic or renal insufficiency incompatible with fluciclovine f-18 (221 mci/ml injection, solution) clearance. Logged tolerability patterns center on nausea (8.5% of reports), headache (7.1% of reports), dizziness (5.1% of reports).
Reconcile eGFR-adjusted medications before escalating Fluciclovine F-18 in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Fluciclovine F-18 maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Fluciclovine F-18 (Fluciclovine F-18) components
- Uncompensated hepatic or renal insufficiency incompatible with Fluciclovine F-18 (221 mCi/mL Injection, Solution) clearance
Logged Side-Effect Incidence (6 Reports)
Fluciclovine F-18 Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fluciclovine F-18)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Biochemical Relapse-Free Survival in Postprostatectomy Patients Receiving Patients initially planned for WP radiation with field decision change to PB-only radiation after PET showed (1) no significant difference in 3-year bRFS compared with patients initially planned for PB-only radiation; and (2)... Practical radiation oncology • 2024-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39032598 ↗ |
Fluciclovine F-18 Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.7100/unit (~$51.30/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $190.49 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $77.75 / mo | View logs ↓ |
Fluciclovine F-18 Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Fluciclovine F-18 RxNorm Concept ID | RXN-69932001-1754 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.7100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $190.49 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $77.75 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Fluciclovine F-18 Patient Community, Cohort Filters & Dosage Logs
Cross-verified Fluciclovine F-18 (radioactive diagnostic agent) monograph synthesizing RxNorm RXN-69932001-1754, openFDA FAERS signals, and $77.75–$190.49 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Fluciclovine F-18 community threads and patient logs by age, biological sex, dosage, and treatment duration.